VERA is trading at 5.7% down now at $40.22 after no clear company-specific catalyst surfaced in the available news flow.
The stock’s move appears consistent with a pullback from recent strength, with VERA closing at $42.66 on July 1 after a strong late-June run. Broader U.S. markets are mixed-to-firmer, so the decline looks more idiosyncratic than macro-driven. No earnings, FDA, or major corporate announcement was identified in the sources.